Celgene NEWS

Poseida, Legend/Janssen Look To Snag Celgene/Bluebird's BCMA Crown  -  Scrip
Poseida and Legend/Janssen aim to develop CAR-T therapies with improved efficacy and safety, and both programs delivered updates at ASH for BCMA-targeting CAR-T candidates in multiple myeloma that could challenge Celgene/bluebird's lead in this ...

Global Hematology Market Overview 2018-2025: Celgene, Novartis, Pfizer, Roche, Sanofi  -  MRS Research Blog (press release) (blog)
QY Market Research added a new 110+ pages research report with TOC (Table of Contents) titled “Hematology Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2023” in its database that focuses on Hematology Market and ...

Ash 2018 – Legend's mystery CAR raises more questions  -  Vantage
Dr Damian Green of Seattle Children's Hospital said his group was working on giving patients a gamma-secretase inhibitor to increase BCMA density and improve FCAR143's efficacy. However, of the BCMA assets Celgene got through its Juno takeover the ...

Global Thalidomide Market Analysis 2018-2025: Celgene  -  Plains Ledger
QY Market Research has published the latest report titled Global Thalidomide Market Report 2018. Thalidomide Market report provides global coverage of Thalidomide market data from 2013 to 2018. The Thalidomide report starts with the overview of ...

Global Multiple Myeloma Drugs Market 2018 Scope and Latest Trends 2023: Celgene, Johnson & Johnson, Takeda ...  -  Planet Newsdesk (blog)
Global Multiple Myeloma Drugs market 2018 report frames ideas investigation, observes research, investments in features rich services and products, product distinction, technical inventions, and prices. The Multiple Myeloma Drugs industry research ...

Celgene Videos

19:18:24
Jefferies: Buy Celgene, lowest P/E in history

18:30:00
Celgene Stock - Is Celgene Stock a Buy Today?

05:24:16
Celgene Corporation (CELG) Stock Analysis 2018

15:19:30
Jim Cramer on Tesla, Biogen, Celgene and Groupon

19:49:20
Celgene

13:46:36
Celgene CEO: We're in a miraculous time for cancer

02:17:59
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015

15:06:45
Celgene CEO on deal to acquire Impact Biomedicines

16:26:13
Pharma Industry Is A Competitive Space, Says Former Celgene CEO Bob Hugin | CNBC

13:45:37
Exclusive: Celgene Chairman Bob Hugin on pharma under Trump

Celgene Images

Celgene Corporation (CELG) Inks Deal to Buy Receptos (RCPT ...

Celgene CYM-5442 Ozanimod Dials Down Auto-Immune Response

Celgene broadens immunology presence with Anokion deal ...

Health2047 launches collaboration with Celgene to build ...

Drug Discovery & Alliance Development | Celgene

Celgene Corporation 2016 Q4 - Results - Earnings Call ...

Ulcerative Colitis and Crohn’s Sing Different Tunes - Celgene

Beta-Thalassemia: Current Treatments Not Enough - Celgene

Psoriatic Arthritis Treatments Worth Another Look - Celgene

Cancer therapy and cell replication

Celgene WebSites

Celgene Wiki

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.